CRVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CervoMed Inc (CRVO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there is potential upside due to promising Phase 2 study results, the company's financial performance is weak, and technical indicators do not suggest a favorable entry point. The lack of recent trading signals and significant catalysts further supports a hold recommendation.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 36.03, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock closed at $4.45, below the pivot level of $4.653, with support at $4.203 and resistance at $5.104. Overall, the technical indicators do not suggest a strong buy signal.
The company has generated intriguing data in two Phase 2 studies for neflamapimod, which could potentially lead to disease-modifying activity in dementia with Lewy bodies. Analyst coverage initiated with an Overweight rating, indicating potential upside.
Net income remains negative, though it has improved YoY. No recent news, significant trading trends, or congress trading data to act as a catalyst.
In Q3 2025, revenue dropped to $322,569 (-83.37% YoY). Net income improved to -$7,726,639 (+62.54% YoY), and EPS increased to -0.84 (+52.73% YoY). Gross margin remained at 100%. Despite some improvement in losses, the financial performance remains weak overall.
Cantor Fitzgerald initiated coverage with an Overweight rating, citing significant upside potential due to promising Phase 2 study results for neflamapimod. However, no price target was provided.
